GSK’s Nucala (mepolizumab) Receives the China’s NMPA Approval for Severe Eosinophilic Asthma
Shots:
- GSK’s Nucala (targeting anti-Interleukin-5) has received the NMPA’s approval as an add-on maintenance therapy for treating severe eosinophilic asthma in adults and adolescents of 12yrs. and older
- The approval was based on a 52wk. P-III study evaluating the safety and efficacy of mepolizumab vs PBO, as add-on therapy with 1EP as reduction in the annual rate of clinically significant exacerbations (CSE) in Chinese patients with severe asthma
- The results revealed 65% fewer CSE’s (0.45 vs 1.31 events/year), a 70% decrease in the frequency of CSE per year and an extended period before patients had their first CSE requiring hospitalization or ED visits (3.4% vs 12.6%)
Ref: GSK | Image: GSK
Related News:- GSK Reports the MHLW Acceptance of sNDA for Nucala (mepolizumab) in Adults with Chronic Rhinosinusitis with Nasal Polyps
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
